Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cell stress

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    85 result(s) found for: Cell stress. Displaying page 4 of 5.
    « Previous 1  2  3  4  5  Next»
    EudraCT Number: 2019-002936-97 Sponsor Protocol Number: LTFU-ABO-101 Start Date*: Information not available in EudraCT
    Sponsor Name:Abeona Therapeutics Europe SL.
    Full Title: A Long-term Follow-up Study of Patients with MPS IIIB from Gene Therapy Clinical Trials Involving the Administration of ABO-101 (rAAV9.CMV.hNAGLU)
    Medical condition: MPS IIIB is a devastating lysosomal storage disease, caused by a N-α-acetylglucosaminidase (NAGLU) gene defect. Infants with MPS IIIB appear normal at birth, but the disease is relentlessly progres...
    Disease: Version SOC Term Classification Code Term Level
    20.1 10010331 - Congenital, familial and genetic disorders 10056890 Mucopolysaccharidosis III PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-004467-36 Sponsor Protocol Number: SRA737-02 Start Date*: 2016-04-13
    Sponsor Name:Sierra Oncology, Inc.
    Full Title: A Phase 1/2 Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Gemcitabine plus Cisplatin or Gemcitabine Alone in Subjects with Advanced Cancer
    Medical condition: Histologically or cytologically proven solid tumours where treatment with gemcitabine plus cisplatin or gemcitabine alone is considered appropriate by the Investigator.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10049280 Solid tumour LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-023799-21 Sponsor Protocol Number: H9X-MC-GBDJ Start Date*: 2011-10-06
    Sponsor Name:Eli Lilly & Company
    Full Title: The Effect of Dulaglutide on Major Cardiovascular Events in Patients with Type 2 Diabetes: Researching Cardiovascular Events with a Weekly INcretin in Diabetes (REWIND)
    Medical condition: Cardiovascular events in patients with Type 2 diabetes
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004860 10012654 Diabetic complications cardiovascular HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) LT (Completed) LV (Completed) CZ (Completed) HU (Completed) GB (Completed) PL (Completed) ES (Completed) BG (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-005592-13 Sponsor Protocol Number: FERRICHFII Start Date*: 2014-02-27
    Sponsor Name:King's College London [...]
    1. King's College London
    2. King's College Hospital NHS Foundation Trust
    Full Title: Mechanisms of Exercise Benefit with Intravenous Iron in Chronic Heart Failure: The Ferric Iron in Heart Failure (FERRIC HF) II Trial
    Medical condition: Chronic Heart Failure
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004849 10008908 Chronic heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-001071-20 Sponsor Protocol Number: CFTSp034 Start Date*: 2013-11-14
    Sponsor Name:The Christie NHS Foundation Trust
    Full Title: A Randomised Phase II Study in Metastatic Melanoma to Evaluate the Efficacy of Adoptive Cellular Therapy with Tumour Infiltrating Lymphocytes (TIL) and Assessment of High versus Low Dose Interleukin-2
    Medical condition: Malignant Melanoma
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004864 10027481 Metastatic melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-002101-35 Sponsor Protocol Number: HyperCarD2 Start Date*: 2017-08-24
    Sponsor Name:Sten Madsbad
    Full Title: THE ROLE OF HYPERGLYCEMIA, HYPERINSULINEMIA AND ELEVATED FREE FATTY ACIDS FOR CARDIAC FUNCTION IN PATIENTS WITH TYPE 2 DIABETES – THE HYPERCARD2 STUDY
    Medical condition: typé 2 diabetes
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-003087-40 Sponsor Protocol Number: PHRC-N-2015 Start Date*: 2017-01-17
    Sponsor Name:UHangers
    Full Title: Interest of intraveinous iron and tranexamic acid to reduce transfusion in hip fracture patients - HIFIT Study
    Medical condition: Hip fracture
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-007928-18 Sponsor Protocol Number: Repha_1328 Start Date*: 2008-06-04
    Sponsor Name:REPHA GmbH
    Full Title: Evaluation of efficacy and safety of the herbal drug Myrrhinil-Intest vs. mesalazine in maintaining clinical remission of ulcerative colitis - a 12-month, multicenter, randomized, prospective, doub...
    Medical condition: ulcerative colitis patients in clinical remission
    Disease: Version SOC Term Classification Code Term Level
    9.1 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-004438-18 Sponsor Protocol Number: MeIn/06/NEB-DIA/001 Start Date*: 2008-04-08
    Sponsor Name:A. Menarini Farmaceutica Internazionale s.r.l.
    Full Title: Comparative effects of Nebivolol and Carvedilol on orthostatic hypotension in hypertensive patients with type 2 diabetes mellitus (DIANECA)
    Medical condition: Orthostatic hypotension in hypertensive patients with type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    9.1 10031127 Orthostatic hypotension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) IE (Prematurely Ended) LV (Prematurely Ended) AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-000781-38 Sponsor Protocol Number: sempa1 Start Date*: 2019-05-07
    Sponsor Name:Aarhus University Hospital
    Full Title: Effect of Empagliflozin and Semaglutide on Cardio-Renal Target Organ Damage in patients with type 2 diabetes – A randomized Trial
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2010-021576-28 Sponsor Protocol Number: DFG Fr 1455/6-1 Start Date*: 2011-06-21
    Sponsor Name:Universitätsklinikum Tuebingen
    Full Title: Effects of transfusion thresholds on neurocognitive outcome of extremely low birth weight infants (ETTNO) a blinded randomized controlled multicenter trial
    Medical condition: extreme prematurity anemia of prematurity neurodevelopmental impairment
    Disease: Version SOC Term Classification Code Term Level
    12.1 10002307 Anemia of prematurity LLT
    12.1 10036615 Prematurity LLT
    Population Age: Preterm newborn infants, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-000102-28 Sponsor Protocol Number: AFJ2020-1 Start Date*: 2020-08-19
    Sponsor Name:Mental Healt Center Copenhagen
    Full Title: Does the glucagon-like peptide-1 receptor agonist semaglutide prevent deterioration in glycaemic control in prediabetic or diabetic patients with schizophrenia spectrum disorder treated with the an...
    Medical condition: Schizophrenia spectrum disorder
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10052792 Schizophrenia, undifferentiated type LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-003543-11 Sponsor Protocol Number: 16-214-02 Start Date*: 2017-07-10
    Sponsor Name:Nektar Therapeutics
    Full Title: A Phase 1/2, Open-label, Multicenter Study of the Combination of NKTR-214 and Nivolumab or the Combination of NKTR-214, Nivolumab, and Other Anti-Cancer Therapies in Patients with Select Locally Ad...
    Medical condition: Locally Advanced or Metastatic Solid Tumor Malignancies
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065143 Malignant solid tumour LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing) BE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2009-012784-34 Sponsor Protocol Number: 384/09 Start Date*: 2009-07-08
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: STUDY OF HYDROXYUREA MECHANISMS OF ACTION ON LEUKOCYTE ACTIVATION IN PATIENTS WITH CHRONIC MYELOPROLIFERATIVE SYNDROMES.
    Medical condition: MYELOPROLIFERATIVE SYNDROMES
    Disease: Version SOC Term Classification Code Term Level
    9.1 10015493 LLT
    9.1 10036057 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-004486-86 Sponsor Protocol Number: SRA737-01 Start Date*: 2016-04-25
    Sponsor Name:Sierra Oncology, Inc.
    Full Title: A Phase 1/2 Trial of SRA737 (a Chk1 Inhibitor) Administered Orally in Subjects with Advanced Cancer
    Medical condition: Patients with histologically or cytologically proven advanced solid tumours, refractory to conventional treatment, or for which no conventional therapy is considered appropriate by the Investigator.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10007050 Cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-004786-40 Sponsor Protocol Number: PB-102-F01 Start Date*: 2013-05-10
    Sponsor Name:Protalix Ltd.
    Full Title: A Phase 1/2, Open Label, Dose Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks ...
    Medical condition: Fabry disease
    Disease: Version SOC Term Classification Code Term Level
    17.0 10010331 - Congenital, familial and genetic disorders 10016016 Fabry's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2010-019290-15 Sponsor Protocol Number: IMCgp100/01 Start Date*: 2010-08-13
    Sponsor Name:Immunocore Ltd
    Full Title: A Phase I/II, Open label, Dose Finding Study to Assess the Safety, Tolerability and Efficacy of IMCgp100, a Monoclonal T Cell Receptor anti-CD3 scFv Fusion Protein in Patients With Advanced Maligna...
    Medical condition: Advanced Malignant Melanoma in patients with Stage IV or unresectable Stage III disease for whom no standard effective therapy exists.
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10053571 Melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-001989-38 Sponsor Protocol Number: IMCRELA Start Date*: 2021-07-08
    Sponsor Name:Facultad de medicina y ciencias de la salud de la Universidad Católica de Valencia
    Full Title: IMPACT OF THE COMBINED TREATMENT OF THE LIPOSOMATED POLYPHENOLS CÚRCULA AND RESVERATROL® WITH DUTASTERIDE, IN THE CLINICAL IMPROVEMENT OF PATIENTS WITH ALS TREATED WITH RILUZOLE
    Medical condition: Amyotrophic Lateral Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-003350-41 Sponsor Protocol Number: APOCT-003 Start Date*: 2017-03-28
    Sponsor Name:Division pf Paediatric and Adolescent Medicine, Oslo University Hospital
    Full Title: The Diabetes Virus Detection and Intervention Trial (DiViDIntervention)
    Medical condition: Newly diagnosed Type 1 Diabetes diagnosed within the previous three weeks at time of screening. Female and male patients between the ages of 6 and 15 years will be recruited.
    Disease: Version SOC Term Classification Code Term Level
    19.1 10027433 - Metabolism and nutrition disorders 10067584 Type 1 diabetes mellitus PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NO (Completed) SE (Ongoing) DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-002507-34 Sponsor Protocol Number: GSN000200 Start Date*: 2014-02-20
    Sponsor Name:Genkyotex Innovation SAS
    Full Title: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Study Evaluating the Safety and Efficacy of Oral GKT137831 in Patients with Type 2 Diabetes and Albuminuria
    Medical condition: Patients with type 2 diabetes and albuminuria.
    Disease: Version SOC Term Classification Code Term Level
    17.0 10038359 - Renal and urinary disorders 10061835 Diabetic nephropathy PT
    17.0 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    17.0 10038359 - Renal and urinary disorders 10001580 Albuminuria PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) PL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 31 20:43:26 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA